ArticleJournal, genetic engineering & biotechnology2026
Dual targeting of IGF-1R and K-RAS with natural phytochemicals for lung cancer therapy: an in-silico study.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, and the limitations and adverse effects of conventional chemotherapy necessitate the exploration of alternative therapeutic strategies. In this study, we used in-silico methods to identify bioactive compounds from medicinal plants with potential anti-lung cancer activity. We aimed to find potential inhibitors for the prevention of lung cancer, which can target two important proteins-insulin-like growth factor receptor (IGF-1R) and Kirsten rat sarcoma viral oncogene homologue (KRAS). A library of 1584 phytochemicals derived from 12 medicinal plants was retrieved from the IMPPAT 2.0 database and virtually screened using PyRx 0.8 software. According to the results, 17Beta-Hydroxywithanolide K and Ginkgolide A demonstrated strong binding affinity to IGF-1R (-9.4 Kcal/mol) and KRAS (-6.9 Kcal/mol), respectively, compared to the synthetic inhibitors Picropodophyllin (-7.7 Kcal/mol) and Sotorasib (-5.9 Kcal/mol). Pharmacokinetic (ADME) and toxicity analysis indicated favorable characteristics, including high gastrointestinal absorption and non-toxicity. Molecular dynamics (MD) simulations of 100 ns duration confirmed the stability of the protein-ligand complex. Overall, 17Beta-Hydroxywithanolide K and Ginkgolide A have potential as natural therapeutic agents for the treatment of lung cancer. However, additional in vitro and in vivo experiments are needed to validate these computational results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.